METHOTREXATE (MTX) - PHARMACOLOGY IN PATIENTS RECEIVING INTENSIVE MTX/6MERCAPTOPURINE (6MP) CONSOLIDATION FOR ACUTE LYMPHOCYTIC-LEUKEMIA (ALL) - A PEDIATRIC ONCOLOGY GROUP-STUDY

被引：0
|
作者：
GRAHAM, M
CAMITTA, B
LAUER, S
LEVENTHAL, B
CASPER, J
CIVIN, C
CHEO, D
ZUHARUK, M
机构：
[1] JOHNS HOPKINS UNIV HOSP,CTR ONCOL,BALTIMORE,MD 21205
[2] MED COLL WISCONSIN,MIDWEST CHILDRENS CANC CTR,MILWAUKEE,WI 53226
来源：
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH | 1988年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：226 / 226
页数：1
相关论文
共 50 条
  • [41] Effect of High-Dose Methotrexate (HD-MTX) Vs Capizzi Methotrexate/Pegaspargase (C-MTX/ASNase) on Osteonecrosis (ON) Incidence in Children and Young Adults with T-Acute Lymphoblastic Leukemia (T-ALL): Results of Children's Oncology Group (COG) Study AALL0434
    Mattano, Leonard A.
    Devidas, Meenakshi
    Chen, Si
    Esiashvili, Natia
    Asselin, Barbara
    Winick, Naomi J.
    Loh, Mignon
    Raetz, Elizabeth A.
    Hunger, Stephen
    Carroll, William L.
    Winter, Stuart S.
    Dunsmore, Kimberly P.
    BLOOD, 2014, 124 (21)
  • [42] Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study
    Amylon, MD
    Shuster, J
    Pullen, J
    Berard, C
    Link, MP
    Wharam, M
    Katz, J
    Yu, A
    Laver, J
    Ravindranath, Y
    Kurtzberg, J
    Desai, S
    Camitta, B
    Murphy, SB
    LEUKEMIA, 1999, 13 (03) : 335 - 342
  • [43] Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study
    MD Amylon
    J Shuster
    J Pullen
    C Berard
    MP Link
    M Wharam
    J Katz
    A Yu
    J Laver
    Y Ravindranath
    J Kurtzberg
    S Desai
    B Camitta
    SB Murphy
    Leukemia, 1999, 13 : 335 - 342
  • [44] REPETITIVE LOW-DOSE ORAL METHOTREXATE AND INTRAVENOUS MERCAPTOPURINE TREATMENT FOR PATIENTS WITH LOWER RISK B-LINEAGE ACUTE LYMPHOBLASTIC-LEUKEMIA - A PEDIATRIC-ONCOLOGY-GROUP PILOT-STUDY
    MAHONEY, DH
    CAMITTA, BM
    LEVENTHAL, BG
    SHUSTER, JJ
    CIVIN, CJ
    GANICK, DJ
    LAUER, SJ
    STEUBER, CP
    KAMEN, BA
    CANCER, 1995, 75 (10) : 2623 - 2631
  • [45] Results of a pilot study of dose intensification of methotrexate (MTX) and cyclophosphamide (CP) in patients with advanced-stage (III/IV) small non-cleaved non-Hodgkin's lymphoma and B-cell ALL (B-ALL): A pediatric oncology group study.
    Griffin, T
    Mahmoud, H
    Weitzman, S
    Schwenn, M
    Hutchison, R
    Ricketts, R
    Kepner, J
    Murphy, S
    BLOOD, 2000, 96 (11) : 135A - 135A
  • [46] Delayed intensification (DI) enhances event-free survival (EFS) of children with B-precursor acute lymphoblastic leukemia (ALL) who received intensification therapy with six courses of intravenous methotrexate (MTX): POG 9904/9905: A Childrens Oncology Group study (COG)
    Winick, Naomi
    Martin, Paul L.
    Devidas, Meenakshi
    Shuster, Jonathan
    Borowitz, Michael J.
    Bowman, Paul
    Laren, Eric
    Pullen, Jeanette
    Hunger, Stephen P.
    Carroll, William L.
    Camitta, Bruce M.
    BLOOD, 2007, 110 (11) : 179A - 180A
  • [47] Consolidation therapy with intermediate dose methotrexate (IDM) alone, or IDM and L-asparaginase (ASP), or IDM and cytosine arabinoside (ARAC) in standard risk acute lymphoblastic leukemia (ALL) of childhood: A pediatric oncology group (POG) study.
    Harris, MB
    Land, VJ
    Shuster, JJ
    Borowitz, MJ
    Behm, FG
    Pullen, DJ
    BLOOD, 1996, 88 (10) : 2661 - 2661
  • [48] BIOLOGICAL EFFECTS OF N-(4-(N-((2-AMINO-4-HYDROXY-6-QUINAZOLINYL)METHYL)PROP-2-YNYLAMINO)BENZOYL)-L-GLUTAMIC ACID (CB3717) ON HUMAN ACUTE LYMPHOCYTIC-LEUKEMIA CELL-LINES RESISTANT TO METHOTREXATE (MTX) OR TRIMETREXATE (TMQ)
    TAKEMURA, Y
    OHNUMA, T
    ARKIN, H
    HOLLAND, JF
    CALVERT, AH
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 230 - 230
  • [49] Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0–45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol
    Linea Natalie Toksvang
    Bodil Als-Nielsen
    Christopher Bacon
    Ruta Bertasiute
    Ximo Duarte
    Gabriele Escherich
    Elín Anna Helgadottir
    Inga Rinvoll Johannsdottir
    Ólafur G. Jónsson
    Piotr Kozlowski
    Cecilia Langenskjöld
    Kristi Lepik
    Riitta Niinimäki
    Ulrik Malthe Overgaard
    Mari Punab
    Riikka Räty
    Heidi Segers
    Inge van der Sluis
    Owen Patrick Smith
    Marion Strullu
    Goda Vaitkevičienė
    Hilde Skuterud Wik
    Mats Heyman
    Kjeld Schmiegelow
    BMC Cancer, 22
  • [50] Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol
    Toksvang, Linea Natalie
    Als-Nielsen, Bodil
    Bacon, Christopher
    Bertasiute, Ruta
    Duarte, Ximo
    Escherich, Gabriele
    Helgadottir, Elin Anna
    Johannsdottir, Inga Rinvoll
    Jonsson, Olafur G.
    Kozlowski, Piotr
    Langenskjold, Cecilia
    Lepik, Kristi
    Niinimaki, Riitta
    Overgaard, Ulrik Malthe
    Punab, Mari
    Raty, Riikka
    Segers, Heidi
    van der Sluis, Inge
    Smith, Owen Patrick
    Strullu, Marion
    Vaitkeviciene, Goda
    Wik, Hilde Skuterud
    Heyman, Mats
    Schmiegelow, Kjeld
    BMC CANCER, 2022, 22 (01)
12345